- Home
- PLAG vs CMMB Comparison
PLAG vs CMMB Comparison
Compare PLAG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLAG
- CMMB
- Stock Information
- Founded
- PLAG 1986
- CMMB 2004
- Country
- PLAG United States
- CMMB Israel
- Employees
- PLAG N/A
- CMMB N/A
- Industry
- PLAG Packaged Foods
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- PLAG Consumer Staples
- CMMB Health Care
- Exchange
- PLAG Nasdaq
- CMMB Nasdaq
- Market Cap
- PLAG 12.8M
- CMMB 13.7M
- IPO Year
- PLAG N/A
- CMMB N/A
- Fundamental
- Price
- PLAG $2.25
- CMMB $3.22
- Analyst Decision
- PLAG
- CMMB Strong Buy
- Analyst Count
- PLAG 0
- CMMB 2
- Target Price
- PLAG N/A
- CMMB $26.50
- AVG Volume (30 Days)
- PLAG 140.9K
- CMMB 280.1K
- Earning Date
- PLAG 11-14-2025
- CMMB 11-13-2025
- Dividend Yield
- PLAG N/A
- CMMB N/A
- EPS Growth
- PLAG N/A
- CMMB N/A
- EPS
- PLAG N/A
- CMMB N/A
- Revenue
- PLAG $6,069,007.00
- CMMB N/A
- Revenue This Year
- PLAG N/A
- CMMB N/A
- Revenue Next Year
- PLAG N/A
- CMMB N/A
- P/E Ratio
- PLAG N/A
- CMMB N/A
- Revenue Growth
- PLAG N/A
- CMMB N/A
- 52 Week Low
- PLAG $0.47
- CMMB $2.39
- 52 Week High
- PLAG $5.52
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- PLAG 56.48
- CMMB 57.30
- Support Level
- PLAG $2.02
- CMMB $3.11
- Resistance Level
- PLAG $2.83
- CMMB $3.50
- Average True Range (ATR)
- PLAG 0.29
- CMMB 0.24
- MACD
- PLAG 0.03
- CMMB -0.01
- Stochastic Oscillator
- PLAG 47.27
- CMMB 62.49
About PLAG Planet Green Holdings Corp.
Planet Green Holdings Corp is a diversified technology and consumer products company with a presence in North America and China engaged in Chemical Products, Tea Products, and Online Advertising Services. The company operates in three segments namely to grow, produce, and distribute Cyan brick tea, black tea, and green tea in China; to research, develop, manufacture, and sell chemical products including formaldehyde, urea formaldehyde adhesive, methylal, ethanol fuel, fuel additives and clean fuel in China; and to develop and operate a demand-side platform which empowers buyers of advertising to manage and optimize their digital advertising across different real-time bidding networks in North America and China.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.